About
Andrew Fraley, Ph.D., is a biotech entrepreneur and scientist focused on RNA therapeutics, genetic medicine, and company creation. Shift Bioscience's official materials currently associate him with senior leadership there, with the company overview listing him as Executive Chair and his individual bio page listing him as Chief Strategy Officer. He is also described publicly as the Founding and Managing Partner of Sunrise BioVentures, and as a co-founder of Korro Bio, Triplet Therapeutics, and Judo Bio, after earlier serving as Head of Chemistry at Moderna.
Areas of interest
biotechRNA therapeuticsnucleic acid therapeuticsRNA editinggene regulationoligonucleotide deliverygenetic medicinekidney-targeted therapeuticscell rejuvenationlongevity